These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18846540)

  • 1. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Markman M
    Cancer; 2008 Nov; 113(10):2832-3; author reply 2833-4. PubMed ID: 18846540
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
    Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents and new formulations for the treatment of ovarian cancer.
    Sabbatini P
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):840-2. PubMed ID: 16491624
    [No Abstract]   [Full Text] [Related]  

  • 4. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
    Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for ovarian cancer.
    Kaye SB
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
    [No Abstract]   [Full Text] [Related]  

  • 8. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels.
    Fleming LW
    Scott Med J; 2001 Jun; 46(3):81-3. PubMed ID: 11501326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
    Markman M
    Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA-125: an evolving role in the management of ovarian cancer.
    Markman M
    J Clin Oncol; 1996 May; 14(5):1411-2. PubMed ID: 8622053
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting angiogenesis in cancer: clinical development of bevacizumab.
    Kerr DJ
    Nat Clin Pract Oncol; 2004 Nov; 1(1):39-43. PubMed ID: 16264798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenetic agents for solid tumors].
    Blay JY
    Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
    [No Abstract]   [Full Text] [Related]  

  • 20. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.